Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall Street divided ...
One analyst sees expanded uses for Rinvoq and Skyrizi propelling AbbVie stock to as much as $315 per share. This bull case makes sense and could be bolstered by AbbVie's further efforts to expand its ...
Oct 2 (Reuters) - US drugmaker AbbVie (ABBV.N), opens new tab said on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines. Here ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
NORTH CHICAGO, Ill.– AbbVie (NYSE: ABBV), a global pharmaceutical leader, and the PGA TOUR announced Tuesday a partnership naming AbbVie the Official Pharmaceutical Sponsor of the PGA TOUR and the ...
AbbVie now plans to submit the results to global regulators in hopes of securing a Qulipta expansion. (AbbVie) With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach ...
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether ...
AbbVie Inc. reported second quarter profit and sales that topped Wall Street’s expectations, driven by strong demand across its immunology and neuroscience franchises and further signs of a recovery ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AbbVie (ABBV) announced Monday a $10.9 billion plan to acquire Apogee Therapeutics (APGE), strengthening its immunology pipeline and sending Apogee stock flying. The deal "helps partially solve one of ...
AbbVie ABBV-0.12%decrease; down pointing triangle has agreed to buy Apogee Therapeutics APGE-0.01%decrease; down pointing triangle for about $10.9 billion to bolster the pharmaceutical company’s core ...
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen immunology pipeline. The acquisition, one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results